Kalexo Bio Deal History & Licensing Activity
Kalexo Bio is a life sciences. Over the past three years, Kalexo Bio has been involved in 2 licensing and acquisition transactions, with a primary focus on Oligonucleotides (4 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Oligonucleotides
Focus Area
Cardiovascular
Kalexo Bio Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Kalexo Bio in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| dual-target siRNA | Mabwell | Oligonucleotides | Unknown | license | Jul 2025 |
| siRNA | Kalexo | Oligonucleotides | Unknown | collaboration | Jul 2025 |
Kalexo Bio Pipeline Focus
Therapeutic areas and modalities where Kalexo Bio is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Kalexo Bio Strategic Signals
Key indicators of Kalexo Bio's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Kalexo Bio's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Cardiovascular assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Kalexo Bio Licensing & Deal Activity
Kalexo Bio is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Kalexo Bio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Kalexo Bio include Cardiovascular (4 deals and trials). In terms of modality, Kalexo Bio has shown particular interest in oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Kalexo Bio and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Kalexo Bio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.